
Sanofi’s Soliqua proves superior to GLP-1 RA therapies in reducing blood sugar levels
pharmafile | June 10, 2019 | News story | Research and Development, Sales and Marketing | Sanofi, Soliqua, diabetes, pharma, type 2 diabetes
Sanofi has stepped up at the American Diabetes Association (ADA) 79th Scientific Sessions in San Francisco, revealing new data which indicate that Soliqua (insulin glargine and lixisenatide) met its primary endpoint in the treatment of type 2 diabetes patients.
According to the findings, Soliqua demonstrated a “statistically superior reduction of average blood sugar level (HbA1C)” after 26 weeks of treatment compared to continued GLP-1 RA therapy when receiving Sanofi’s drug once weekly or daily.
Specifically, it was found that a higher proportion of patients switching to Soliqua reported HbA1C levels of lower than the ADA’s recommendation of 7%, as well as without documented symptomatic hypoglycaemia, compared to continued GLP-1 RA therapy.
“We are committed to providing people living with diabetes a broad range of options that can help support personalised care,” commented Rachele Berria, Global Head of Diabetes Medical Affairs at Sanofi. “As the first comparison between Soliqua and both daily and weekly GLP-1 RA treatments, this study provides physicians with new data that they could use when considering Soliqua as a part of a personalised treatment plan.”
Matt Fellows
Related Content

Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria
Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

Sanofi’s treatment granted orphan designation for rare chronic inflammatory condition
The European Medicines Agency has granted orphan designation to Sanofi’s investigational Bruton’s tyrosine kinase (BTK) …






